• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtronic touts trial results for InPen smart insulin pen, extended infusion system

June 28, 2021 By Sean Whooley

Medtronic logo updatedMedtronic (NYSE:MDT) today presented positive study results for its InPen smart insulin pen and its extended-wear infusion set.

Fridley, Minn.-based Medtronic touted real-world clinical results comparing glycemic outcomes for 1,736 individuals before and after using the InPen smart insulin pen for 90 days with a continuous glucose monitor (CGM).

According to a news release, data from the real-world study demonstrated an increase in time-in-range of 2.3% for those whose glucose management indicator (GMI) was >8% and an increase of 5% time-in-range for people whose GMI was >9.5%. For both groups, no subjects experienced an increase in time below range (hypoglycemia) during the study period.

The company also touted data showing that the InPen provided improved dosing decision support as demonstrated by fewer total doses per day and improved glycemic control. The average daily insulin bolus frequency decreased (from 3.7 to 3.6/day and 3.3 to 3.2/day, respectively, for each group). The total rapid-acting daily insulin dose increased (from 26.29 to 27.19 u/day and 27.57 to 29.24 u/day, respectively, for each group), based on data aggregated from individuals who uploaded between January 2018 and October 2020 with a minimum of 30 days of CGM data pre- and post-InPen initiation.

“Smart insulin pens that automatically track insulin doses and calculate active insulin are emerging as important advances in diabetes management technology because they increase the amount of time spent in the preferred glucose range without increasing hypoglycemia,” Park Nicollet International Diabetes Center (Minneapolis) medical director Dr. Anders Carlson said in the release. “It’s encouraging to see that positive clinical gains are possible with the use of consumer-friendly diabetes technology, such as InPen, that makes it simple for patients to track insulin dosing, calculate doses and receive reminders and other decision support that allows them to manage their diabetes more effectively without adding a lot of complexity.”

In addition to the InPen data, Medtronic presented U.S. pivotal trial data for its Medtronic Extended infusion set, which it touts as the first and only infusion set that can be worn for up to seven days.

Data covered the safety and performance of 259 individuals between ages 18 and 80 years old who wore traditional 2-day or 3-day infusion sets with the MiniMed 670G system for two weeks, followed by 12 consecutive wears of the Medtronic Extended infusion set.

The study showed no significant increase in the total daily dose of insulin, indicating that the Medtronic Extended infusion set delivers insulin successfully throughout the seven-day wear time. Additionally, no adverse events were observed, Medtronic said. The Medtronic Extended infusion set is limited to investigational use in the U.S. but is CE marked in Europe.

“For decades, insulin infusion sets needed to be changed every two to three days. So, the development of an extended infusion set that can be worn for up to seven days represents a significant improvement in the patient experience,” Stanford emeritus professor of pediatrics & endocrinology Dr. Bruce Buckingham said. “The pivotal trial demonstrated the safety of the new infusion set as well as increased satisfaction from being able to wear it longer.

“Alleviating the burden of changing infusion sets every two to three days is a very meaningful improvement in the overall pump experience. This important innovation in the infusion set will make insulin pump therapy feel easier for many patients.”

Filed Under: Auto-injectors, Clinical Trials, Diabetes, Drug-Device Combinations, Featured Tagged With: Medtronic

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS